Thus, treatments that support normal metabolism may protect from IOP elevation in individuals with LMX1B variants including both developmental glaucoma and POAG patients (Gharahkhani et al., 2021; Khawaja et al., 2018; MacGregor et al., 2018; Choquet et al., 2018; Gao et al., 2018; Sweeney et al., 2003; Chen et al., 1998; Vollrath et al., 1998; Choquet et al., 2017). This evidence concerns the gene LMX1B and open-angle glaucoma.